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Abstract
Glutamate plays a key role in modulation of nociceptive processing. This excitatory amino acid exerts its action through two distinct
types of receptors, ionotropic and metabotropic glutamate receptors (mGluR). Eight mGluR have been identified and divided in three
groups based on their sequence similarity, pharmacology and G-protein coupling. While the role of group I and II mGluRs is now
well established, little is known about the part played by group III mGluRs in pain. In this work, we studied comparatively the
involvement of spinal group III mGluR in modulation of acute, inflammatory and neuropathic pain. While intrathecal injection of
ACPT-I, a selective group III mGluR agonist, failed to induce any change in vocalization thresholds of healthy animals submitted to
mechanical or thermal stimuli, it dose-dependently inhibited the nociceptive behavior of rats submitted to the formalin test and the
mechanical hyperalgesia associated with different animal models of inflammatory (carrageenan-treated and monoarthritic rats) or
neuropathic pain (mononeuropathic and vincristine-treated rats). Similar effects were also observed following intrathecal injection of
PHCCC, a positive allosteric modulator of mGlu4. Antihyperalgesia induced by ACPT-I was blocked either by LY341495, a non
selective antagonist of mGluR, and by MAP4, a selective group III antagonist. This study provide new evidences supporting the role
of spinal group III mGluRs in the modulation of pain perception in different pathological pain states of various etiologies but not in
normal conditions. It more particularly highlights the specific involvement of mGlu4 in this process and may be a useful therapeutic
approach to chronic pain treatment.
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INTRODUCTION
Glutamate, released in the dorsal horn of the spinal cord from primary afferent fibers after noxious stimuli, activates two types of
receptors: ionotropic (iGluRs) and metabotropic receptors (mGluRs). The iGluRs are ligand-gated ion channels responsible of fast synaptic
transmission ( ). The mGluRs belong to the large family of G-protein coupled receptors and are responsible for theMadden 2002
neuromodulatory activity of glutamate ( ; ). The mGluRs family is composed of 8 members divided inBockaert and Pin 1999 Pin et al. 2005
3 groups, based on sequence homologies, coupling to second messengers systems and pharmacology. Group I mGluRs (mGlu1,5
receptors), primarily stimulate phosphoinositide hydrolysis whereas group II (mGlu2,3) and group III (mGlu4,6,7 and 8) are negatively
coupled to adenylate cyclase. The mGluRs are widely distributed throughout the central nervous system and play important roles in
regulating cell excitability and synaptic transmission. One of the primary functions of group II and III mGluRs is a presynaptic
autoreceptor role involved in reducing glutamate transmission at glutamatergic synapses. They also serve as heteroreceptors involved in
reducing GABA release at inhibitory synapses. Finally, postsynaptically localized mGluRs (primarily of group I) often play an important
role in regulating neuronal excitability and in regulating currents through ionotropic glutamate receptors.
The mGluRs regulate nociceptive processes at different levels of the nervous system and are critically involved in central sensitization
which is associated with chronic pain ( ). Thus, these receptors appear as interesting targets for the development ofWoolf and Salter 2000
new analgesics. Present data in literature indicate that blocking group I mGluRs or activating group II or III mGluRs produce
antinociceptive effects ( ; ; ; ). However, due to the lack of specificNeugebauer 2001 2002 Varney and Gereau 2002 Neugebauer 2007
pharmacology, assessing the specific roles of the different mGluRs in pain is difficult ( ). It is particularly the case forNeugebauer 2007
group III mGluRs. Indeed, while group I and II involvement in pain is well documented, the specific role of group III mGluRs is still
Pain. Author manuscript
Page /2 14
poorly understood. However, group III mGluRs are especially abundant all along the nociceptive pathways and particularly in the
terminals of primary afferent fibers in the dorsal horn of the spinal cord, a key localization for the regulation of ascending informations (Li
; ).et al. 1997 Azkue et al. 2001
This work is focused on the less studied group III mGluRs in pain modulation. We have comparatively studied the involvement of
spinal group III mGluRs both in acute and various chronic pain models in rats, using ACPT-I, a selective group III mGluR agonist (Acher
), and PHCCC, a selective mGlu4 positive allosteric modulator ( ; ) following intrathecalet al. 1997 Maj et al. 2003 Marino et al. 2003
injection. We show here that ACPT-I or PHCCC reduced mechanical hyperalgesia in inflammatory and neuropathic pain models without
affecting behavioral reactions to painful stimuli in healthy animals. This study clearly demonstrates that activation of spinal group III
mGluRs and mGlu4 in particular inhibits the transmission of pain in chronic pain models of various etiologies but not in normal
conditions.
MATERIALS AND METHODS
Cell culture, transfection and functional assay
HEK293 cells were cultured in Dulbecco s modified Eagle s medium supplemented with 10  FCS and antibiotics (Penicillin and’ ’ %
Streptomycin, 100 U/ml final). Culture medium, foetal calf serum (FCS) and other products used for cell culture were purchased from
GIBCO-BRL-Life Technologies, Inc. (Cergy Pontoise, France). Glutamate-pyruvate transaminase (GPT) was purchased from Roche
(Basel, Switzerland).
Cells were transiently transfected with rat clones of group I (mGlu1,5), group II (mGlu2,3) or group-III mGlu receptors by
electroporation as described elsewhere ( ). To avoid any influence of glutamate released by the cells in the assay medium,Brabet et al. 1998
the high affinity glutamate transporter EAAC1 was also co-transfected with the receptor. Since group-II and group-III mGluRs are
naturally couple to the adenylyl-cyclase pathway through Gi/o-protein activation, these receptors were co-transfected with a chimeric
G-protein which is recognized by these receptors but couples to the phospholipase-C pathway and thus lead to inositol phosphate (IP)
production following receptor activation ( ). Receptor activity was then determined by IP measurement.Gomeza et al. 1996
Inositol phosphate accumulation experiments were performed in 96-well microplates as already described ( ).Goudet et al. 2004
Briefly, following transfection, cells were incubated overnight with H-myoinositol (16 Ci/mmol; Amersham, Buckinghamshire, UK). The3
next day, cell medium was removed, cells were rinsed and ambient glutamate degraded by incubation in presence of GPT. Cells were
stimulated by ACPT-I (Tocris Cookson Ltd., Bristol, UK) for 30 minutes then the medium was removed and cells incubated with cold 0.1
M formic acid which induced cell lysis. Then H-IP produced following receptor stimulation were recovered by ion exchange3
chromatography using a Dowex resin (Biorad). IP kept by the resin were then eluted by a solution highly concentrated in formate (4 M),
collected in a 96-wells sample plate, mixed with liquid scintillator (Perkin Elmer). The radioactivity remaining in the membranes is used to
normalize the IP produced. Membranes were solubilized with a solution of NaCl (0.1 M) containing 10  of Triton X100 (Sigma), the%
resulting solution was then collected in a 96-well sample plate and mixed with liquid scintillator. Radioactivity was counted using a
Wallac 1450 Microbeta stintillation and luminescence counter (Perkin Elmer). Results are expressed as the ratio between IP and the total
radioactivity corresponding to IP plus membrane. All points are realized in triplicate.
The dose-response curves were fitted using the GraphPad Prism program and the following equation: y (y y )/(1 (x/EC ) ) y=[ max− min + 50 n ]+
 where EC  is the concentration of the compound necessary to obtain the half maximal effect and n is the Hill coefficient.min 50
Uptake experiments
Glutamate uptake experiments were performed as already described ( ). Briefly, whole brains from male rats werePin et al. 1984
homogenized in ice cold sucrose (0.32M) and centrifuged at 1000 g for 10 minutes at 4 C. The supernatant was then centrifuged at 17.000°
g during 20 minutes. The resulting pellet was lysed in cold water for 45 minutes. Membranes were then centrifuged at 20.000 g during 35
minutes, washed and resuspended in 50mM Tris-citrate buffer (pH7.4). H-glutamate (50 Ci/mmole) was purchased from American3
Radiolabeled Chemicals, Inc. (St Louis, U.S.A.). Uptake of H-glutamate was measured by incubating 100 L of membrane suspension,3 μ
50 L of 3H-glutamate (final concentration of 100 nM) and 50 L of buffer containing or not unlabeled displacing substances at variousμ μ
concentrations (L-glutamate, L-AP4 or ACPT-I), in presence of 2.5 mM CaCl . The final protein concentration was 2 mg/mL. After 102
minutes, the incubation was stopped by addition of 3 mL of cold buffer and filtered on filter paper (FP205, Whatman GF/C). Filter was
washed twice with 3 mL buffer and counted in a Tricarb liquid scintillation counter (Packard). Specific uptake was determined by
substracting the non specific binding in presence of 250 M unlabeled glutamate from the total binding.μ
Animals
Adult male Sprague Dawley rats weighting 175 200 g were purchased from Charles River. Animals were housed under controlled– –
environmental conditions (22 C; 55  humidity) and kept under a 12/12h light/dark cycle, with food and water  for a week prior° % ad libitum
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to start the experiments in order to acclimatize. Animal care and experiments were carried out in accordance with the Committee for
Research and Ethical Issues of the IASP ( ).Zimmermann 1983
Behavioral testing
Paw pressure test
The animals were submitted to the paw pressure test previously described by Randall and Selitto (1957). Nociceptive thresholds,
expressed in grams (g), were measured with a Ugo Basile analgesimeter (Apelex, tip diameter of the probe: 1 mm, weight: 30 g) by
applying an increasing pressure to the right hind paw of rats until a squeak (vocalization threshold) was obtained (cut-off was 750 g). The
treatments were done after the measurement of two consecutive stable vocalization threshold values and their effects were assessed 15, 30,
45, 60, 90 and 120 min after.
Formalin test
Following acclimatization for 20 min in the test chamber, rats received 50 L of 2.5  formalin injected subcutaneously (s.c.) into theμ %
plantar surface of the hind paw. They were then replaced in the Plexiglas box. Biting and licking of the injected paw were monitored by
measuring the total duration of the response in seconds during the two peaks of the typical biphasic pain behavior previously described (
; ). The spontaneous aversive response corresponding to the early phase was assessed duringWheeler-Aceto et al. 1990 Oyama et al. 1996
the first 5 min. The second peak of aversive behavior was observed from 20 to 40 min after formalin administration. Drug treatments
(ACPT-I, saline i.t.) were performed 15 min before formalin injection.
Tail immersion test
The tail of the rat was immersed in a hot water bath maintained at 46 C. The time latency for tail withdrawal was then determined and°
a cut-off time of 30 s was applied to avoid injury.
Persistent pain models: Inflammatory pain models
Carrageenan-induced mechanical hyperalgesia
Thresholds to mechanically induced vocalization were assessed with rats presenting an hyperalgesia elicited by a subcutaneous
injection of -carrageenan (200 g) into the right hind paw (10 L). Four hours later, vocalization thresholds were significantly decreasedλ μ μ
from 218  30 g to 117  23 g.± ±
Model of monoarthritis
This model was previously described by  ( ). Briefly, on day 0, monoarthritis was induced by aButler et al, 1992 Butler et al. 1992
single intra-articular injection of 0.05 mL of complete Freund s adjuvant (CFA) performed under brief 5  isoflurane anesthesia into the’ %
right ankle. Before injection and 14 days after, rats were submitted to the paw pressure test by applying an increasing pressure to ankle
until a vocalization was obtained (276  35 and 135  29 g, respectively).± ±
Persistent pain models: Neuropathic pain models
Chronic Constriction Injury (CCI) model
Unilateral peripheral mononeuropathy was induced according to the method described by Bennett and Xie ( ).Bennett and Xie 1988
Briefly, after determining vocalization thresholds, rats were anesthetized with sodium pentobarbital (50 mg/kg i.p.) and four chromic gut
(5-0) ligatures were tied loosely (with about 1-mm spacing) around the right common sciatic nerve. The nerve was constricted to a barely
discernible degree, so that circulation through the epineurial vasculature was not interrupted. Only animals presenting a decrease  15  of≥ %
the presurgery value of vocalization threshold were selected, i.e. 90  of ligated animals (pre-surgery value: 269  30 g, pre-drug value:% ±
179  25 g).±
Vincristine-induced mechanical hyperalgesia
This model of neuropathic pain was previously described by  ( ). Briefly, five intravenousAuthier et al, 2003 Authier et al. 2003
injections of 150 g/kg of vincristine (Oncovin , Elly Lilly) were performed every 2 days until a cumulative dose of 750 g/kg wasμ ® μ
reached. Preliminary vocalization thresholds to paw pressure (the mean of two consecutive stable values which do not differ more than 10
) were determined before the beginning of vincristine treatment (control pre-injury value: 296  32 g). Only animals with a decrease 15% ± ≥
 of the presurgery value of vocalization threshold were selected, i.e. 73  of injected animals. Hyperalgesia was observed 14 days after% %
the beginning of vincristine treatment (control pre-drug value: 178  28 g).±
Experimental procedure and drugs
Treatment protocol
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For all experiments, treatments, always injected intrathecally, were randomized and administered according to the method of blocks in
order to assess the effect of the different treatments at the same time interval to avoid uncontrolled influences (one block includes a
number of animals corresponding to the number of the different treatments administered; all animals in a same block are tested in the same
short laps of time; the number of blocks corresponds to the number of animals per treatment). Different animals were used for each
experiments (   6 10 per treatment, according to the experiments) performed in a blinded manner in a quiet room and animal behaviorsn = –
were observed by a single experimenter.
Intrathecal injections
Intrathecal injections were performed, under isoflurane anesthesia (4  induction, 2  maintenance), as previously described (% % Mestre et
). Briefly, the anaesthetized rat was held in one hand by the pelvic girdle and a 25-gaugeX1-inch needle connected to a 25 Lal. 1994 μ
Hamilton syringe was inserted into the subarachnoidal space between lumbar vertebrae L5 and L6, until a tail flick was elicited. The
syringe was held in position for few seconds after the injection of a volume of 10 L/rat.μ
Drugs
For intrathecal injections, ACPT-I, LY341495, MAP4 (Tocris Cookson Ltd, Bristol, UK) and PHCCC (Ascent scientific,
Weston-Super-Mare, UK) were dissolved in saline (0.9  NaCl, B. Braun, Melsungen, Germany). All solutions were prepared immediately%
prior to injection.
Expression of results and statistical analysis
The cumulative biting and licking time of each phase of response was generated for each rat in the formalin test. The data (mean ±
SEM) are expressed as time (in s) spent in biting and licking of the hind paw that received formalin. One-way analysis of variance
(ANOVA) was performed and followed by a Student Newman Keuls  test when appropriate. A p<0.05 was taken as statistically– – ’
significant.
For the mechanical pain test, the results are expressed as vocalization thresholds (in grams). To investigate global effects, areas under
the time-course curves (AUCs, g.min) of the antihyperalgesic effects were calculated from individual scores at each time, using the
trapezoidal method. Data were analyzed by a two-way ANOVA followed, when the F value was significant, by a Dunnett s test, when the’
time-course of the effects was studied. One-way ANOVA followed by a Student Newman Keuls  test was used to analyze the effect of the– – ’
different treatments determined by the AUCs. The level of statistical significance was set at p<0.05.
RESULTS
ACPT-I is a selective group III mGluR agonist
Due to the high structural similarity between the different members of each group of the mGluR family, only group selective agonists
and antagonists are available. Indeed, to date, there is no selective agonist of a given subtype of group III mGluRs. However, few group III
selective agonists exist (see ( ) for a review), the best representatives being L-AP4 and ACPT-I.Pin and Acher 2002
To perform the present study we have chosen ACPT-I, a cyclic analog of glutamate, that we previously reported to activate mGlu4,
but was without effect on mGlu1 and mGlu2 ( ). Here we further characterize the effect of this glutamate analog on mostAcher et al. 1997
mGluRs. In HEK293 cells, ACPT-I selectively and dose-dependently activates all group-III receptors expressed and is devoid of
non-specific agonist activity at 100 M on the other members of the mGluR family ( ). From dose-response curves, theμ Fig. 1A and 1B
half-maximal concentration of ACPT-I necessary to yield 50  of the maximal activity (EC50) of group-III receptors can be calculated.%
The mean EC50 value of ACPT-I on mGlu4, mGlu6, mGlu7 and mGlu8 receptors are 1.0  0.2 M (n 6), 13.0  4.6 M (n 4), 2.0  0.1± μ = ± μ = ±
mM (n 3) and 6.3  0.6 M (n 3), respectively. ACPT-I is also devoid of non specific antagonist activity at mGlu1, mGlu2 and mGlu5= ± μ =
receptors (data not shown). Recently, several reports also support a selective action of ACPT-I on group-III mGluRs in vivo (Klak et al.
; ; ).2007 Konieczny et al. 2007 Lopez et al. 2007
Although L-AP4 is commonly used as a group III agonist, this compound also acts at the Cl-dependent glutamate transport (Pin et al;,
), likely the x - transport system ( ). Of interest, whereas L-AP4 inhibits Cl-dependent glutamate transport, ACPT-I1984 c Patel et al. 2004
was far less active at this system ( ). At 100 M, ACPT-I inhibited the chloride-dependent, sodium-independent transport of L-Fig. 1C μ 3
H-Glutamate by 13.8  1.4  (n 3) whereas L-AP4 (100 M) inhibited the uptake by 70.4  17.4  (n 3).± % = μ ± % =
Antinociceptive effect of ACPT-I in healthy animals
Mechanical stimulation
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Intrathecal administration of ACPT-I (20, 40 or 80 g/rat) failed to induce any antinociception in healthy rats submitted to the pawμ
pressure test, in contrast to morphine (10 g/rat) injected in the same conditions which significantly increased the vocalization threshold (μ
).Fig. 2A
Thermal stimulation
The latency of tail withdrawal of healthy rats submitted to tail immersion test was not modified following the intrathecal
administration of ACPT-I (20, 40 or 80 g/rat) while morphine (10 g/rat) injected in the same conditions significantly increased the delayμ μ
of withdrawal ( ).Fig. 2B
Chemical stimulation: formalin test
As can be seen in , ACPT-I significantly and dose-dependently decreased the biting/licking behavior induced by formalinFig. 2C
during both phases of the test. The early phase was significantly reduced by doses equal or higher than 2 g/rat while the late phase wasμ
significantly decreased by doses equal or higher than 10 g/rat. The maximal dose of ACPT-I used (80 g/rat) induced a mean decrease ofμ μ
48  6  (n 6) and 63  10  (n 6) of the first and second phase scores, respectively. This efficacy was not statistically different from that± % = ± % =
of morphine (10 g/rat).μ
ACPT-I inhibited mechanical hyperalgesia in inflammatory pain models
Antihyperalgesic effect of ACPT-I in carrageenan-treated rats
Intrathecal administration of ACPT-I significantly and dose-dependently increased the vocalization threshold of carrageenin-treated
rats submitted to the paw pressure test ( ). Significant difference in time-course of the vocalization threshold started at 20 g/rat andFig. 3A μ
was clearly increased after the administration of 40 and 80 g/rat of ACPT-I. The maximal increase was observed 30 minutes after theμ
injection of 80 g/rat of ACPT-I (mean value of 51  9  (n 8) as compared to the pre-drug value) and the measured vocalizationμ + ± % =
threshold was not statistically different from the corresponding pre-carrageenan mean vocalization threshold (218  7 (n 8) and 208  16 g± = ±
(n 8), respectively) suggesting a reversion of mechanical hyperalgesia by ACPT-I. This dose-dependent effect was confirmed when AUC=
were calculated ( ). In the same conditions, morphine (10 g/rat) administered to carrageenan-treated rats increased the measuredFig. 3A μ
vocalization thresholds higher than the corresponding pre-carrageenan vocalization threshold (mean values of 463  48 g (n 8) and 229 ± = ±
21 g (n 8), respectively)( ).= Fig. 3A
Antihyperalgesic effect of ACPT-I in monoarthritic rats
Two weeks after CFA injection, the mechanical hyperalgesia assessed by the paw pressure test was partially reversed by ACPT-I
injected intrathecally ( ). The vocalization thresholds in rats treated with 40 or 80 g/rat of ACPT-I significantly andFig 3B μ
dose-dependently increased, with a mean maximal increase of 70  16  (n 8) observed 30 minutes after treatment (80 g/rat) as± % = μ
compared to pre-treatment value (from 139  10 g (n 8) to 227  18 g (n 8), 30 minutes after intrathecal injection of ACPT-I at 80 g/rat).± = ± = μ
This effect lasted for 80 minutes after the injection of the highest dose. In the same conditions, morphine (10 g/rat) increased theμ
measured vocalization thresholds higher than the corresponding pre-injury mean vocalization threshold (319  45 g (n 8) and 276  35 g± = ±
(n 8), respectively).=
Influence of ACPT-I in neuropathic pain models
Antihyperalgesic effect of ACPT-I in mononeuropathic rats (CCI model)
The vocalization thresholds of mononeuropathic rats submitted to the paw pressure test were significantly and dose-dependently
increased following intrathecal administration of ACPT-I ( ). Following the administration of 40 and 80 g/rat of ACPT-I,Fig. 4A μ
vocalization threshold time-course was significantly shifted upward, while scores of animals treated with 20 g/rat of agonist remainedμ
equivalent to those of saline-treated animals. The effect due to 80 g/rat was plateauing from 15 to 45 min after injection with a meanμ
maximal increase of 76  13  (n 7) as compared to the pre-drug value. The reached score (mean value: 310  23 g (n 7), 30 minutes± % = ± =
after intrathecal injection) was not statistically different from pre-injury mean value (283  22 g, n 7) suggesting a complete reversion of± =
mechanical hyperalgesia by ACPT-I.
Antihyperalgesic effect of ACPT-I in vincristine-treated rats
Intrathecal injection of ACPT-I significantly and dose-dependently increased the vocalization threshold of vincristine-treated rats
submitted to the paw pressure test ( ). Vocalization threshold time-course was significantly different following the administration ofFig. 4B
40 and 80 g/rat of ACPT-I as compared to saline-treated animals. The maximal increase was observed 45 minutes after the injection ofμ
the 80 g/rat dose (mean increase value of 56  17  (n 8) as compared to the pre-drug value), reached threshold being not statisticallyμ + ± % =
different from corresponding pre-vincristine value (270  36 g (n 8) and 296  32g (n 8), respectively).± = ± =
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Effect of ACPT-I was blocked by mGluRs antagonists
Blockade by a non selective mGluR antagonist, LY341495
In order to verify that ACPT-I antihyperalgesic effect was mediated through its action on mGlu receptors, we used a classical non
selective mGluRs antagonist, LY341495 ( ), co-injected at different doses (62.5, 125 and 250 g/rat) with ACPT-I (80 Pin and Acher 2002 μ μ
g/rat) or saline in carrageenan-treated rats. LY341495 had no effect by itself. The vocalization thresholds of rats treated with LY341495
and saline did not differ significantly from the thresholds measured in rats treated with saline only (data not shown). However, as can be
seen in , increasing doses of LY341495 progressively reduced and almost completely abolished, for the highest dose (250 g/rat)Fig. 5A μ
(mean inhibition: 97  7 , n 7), ACPT-I-induced antihyperalgesia.± % =
Blockade by a selective group III mGluR antagonist, MAP4
Then, to confirm that ACPT-I antihyperalgesic effect was induced by group-III mGlu receptor activation, we used a selective group-III
mGluRs antagonist MAP4 ( ), co-injected at different doses (25, 50 and 100 g/rat) with ACPT-I (80 g/rat) or saline inPin and Acher 2002 μ μ
a model of inflammatory pain, carrageenan-treated rats.  displays the dose-dependent blockade of ACPT-I-inducedFigure 5B
antihyperalgesia by MAP4. At higher dose, MAP4 almost completely abolished the effect of 80 g of ACPT-I, inducing a mean maximalμ
decrease in the antihyperalgesic effect of 81  11  (n 8). In parallel, MAP4 displayed no intrinsic activity, the vocalization threshold of± % =
MAP4  saline treated rats being no significantly different of rats treated only with saline (data not shown).+
Similar experiments with ACPT-I versus ACPT-I  MAP4 were conducted in the CCI model ( ). In mononeuropathic rats,+ Fig. 5C
vocalization thresholds of rats treated with MAP4 (50 g/rat) and saline or saline only, injected intrathecally, were not statisticallyμ
different, illustrating that MAP4 had no effect by itself. However, antihyperalgesic effect of ACPT-I (80 g/rat) was almost completelyμ
abolished (84  6 , n 9) when co-injected with MAP4 (50 g/rat).± % = μ
PHCCC inhibited mechanical hyperalgesia in both inflammatory and neuropathic pain models
In order to identify which receptor among the three group III mGluRs expressed in the spinal cord is involved in the ACPT-I effect,
we performed experiments with the only group III subtype selective compound available today: PHCCC ( ; Maj et al. 2003 Marino et al.
). This compound is a positive allosteric modulator of mGlu4, devoid of activity at the other group III mGluRs.2003
When given via intrathecal route in healthy rats, PHCCC (10, 20 and 40 g/rat) did not affect the vocalization threshold of animalsμ
submitted to the paw pressure test ( ).Fig. 6A
However, intrathecal administration of PHCCC significantly and dose-dependently increased the vocalization threshold of
carrageenan-treated rats submitted to the paw pressure test ( ). This dose-dependent effect was confirmed when AUC wereFig. 6B
calculated ( , right panel). The maximal increase (mean value 84  14  (n 8)) was observed 30 minutes after the injection of 40 Fig. 6A + ± % = μ
g PHCCC per rat (from a pre-drug mean threshold value of 123  7 g (n 8) to 240 19 g (n 8)) and the measured vocalization thresholds± = ± =
was not statistically different from the corresponding pre-carrageenan mean vocalization threshold (223  7 g (n 8)) suggesting a reversion± =
of mechanical hyperalgesia by PHCCC.
In mononeuropathic rats, PHCCC also significantly increased the vocalization threshold in the paw pressure test ( ). The effectFig. 6B
was again dose-dependant with a maximum reached 15 minutes after injection of 40 g (mean value  60  8  (n 8)). and the obtainedμ + ± % =
threshold was not statistically different from that measured before surgery (mean vocalization threshold measured before surgery: 283  5±
g, before injection: 176  7 g, after injection: 270  13 g, (n 10)).± ± =
These data show that like ACPT-I, the mGlu4 selective positive modulator PHCCC reverses the hyperalgesia observed in
inflammatory and mononeuropathic animal models, but does not lead to full analgesia.
DISCUSSION
Using healthy animals, neuropathic pain models from different etiologies (post-traumatic or iatrogenic) and models of more or less
prolonged inflammatory pain, the present study gives an extended picture of the putative analgesic effect resulting from spinal group-III
mGluRs activation. This study further demonstrated that the activation of these receptors by intrathecal administration of a selective
agonist or positive allosteric modulator inhibits the mechanical hypersensitivity associated with the different conditions of intense or
persistent pain while reactions to acute noxious stimuli remain unchanged. Particularly, it highlights the role of mGlu4 in this process.
Among the few selective agonists of group-III mGluRs, we have chosen ACPT-I to perform our experiences ( ). PriorAcher et al. 1997
to behavioural assessment, we further examined the effect of this compound on most mGluRs. We validated that ACPT-I is indeed
selective for group-III mGluRs expressed in a heterologous system, with a preference for mGlu4 over mGlu6,7,8, while presenting no
agonist or antagonist activity on other mGluRs. Moreover, ACPT-I, in contrast to L-AP4 and other mGluR ligands ( ),Patel et al. 2004
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interacts only weakly with the transport system x -. This diminishes any possible unspecific effect of ACPT-I compared to these otherc
ligands. In agreement with this proposal, ACPT-I has already been used with success to assess the role of group III mGluRs in rodent
models of Parkinson disease ( ) and anxiety and depression ( ).Lopez et al. 2007 Klak et al. 2007
Our data show that intrathecally administered ACPT-I had no effect on nociceptive thresholds of healthy rats submitted to mechanical
or thermal stimuli. However, following formalin injection, the nociceptive behavior of rats was significantly and dose-dependently reduced
by ACPT-I in both the first and second phases associated with this pain model. These results confirm the observation by Fisher & Coderre
on the same model using L-AP4 instead of ACPT-I as a group III mGluR agonist ( ). The reduced behavioral scoreFisher and Coderre 1996
in the first phase of the formalin test suggests that group III mGluRs are present at synapses in healthy rats but, seemingly, group III
mGluRs function is more likely to be revealed in conditions of severe and persistent stimulation. Consistent with that, in the different
models of inflammatory and neuropathic pain, we have observed a clear reduction of hyperalgesia.
Intrathecal injection of ACPT-I also suppressed inflammatory pain in two different models with different induction periods. While
inflammation of carrageenan-treated rats is effective few hours after injection, monoarthritis-induced hyperalgesia is clearly obtained in
two weeks following the intra-articular injection of CFA.. Likewise, in both neuropathy models, intrathecal injection of group III agonist
reduces hyperalgesia. These observations are consistent with previous results demonstrating that spinal activation of group III mGluRs by
L-AP4 can decrease the development of mechanical and cold hypersensitivity associated with chronic constriction injury of the sciatic
nerve in rats ( ; ). Testing these different pain models in parallel allowed us to suggest that modulationFisher et al. 2002 Chen and Pan 2005
of hyperalgesia through group III mGluRs appears like a general system, particularly efficient in the inhibition of intense, inflammatory
and neuropathic hyperalgesia.
Although intrathecal injections of ACPT-I results in a very high concentration of ligands at the injection point in a short period of
time, several arguments indicate that the observed effect results from group-III mGluR activation. First, the maximal effect is observed 15
to 30 minutes after the injection, when the compound is likely diluted in the injection area. Second, the effect is inhibited by both the
pan-mGluR antagonist LY341495 as well as by the group-III selective antagonist MAP4. Finally, similar effects were obtained with the
mGlu4 selective positive modulator PHCCC.
It is of interest that ACPT-I and PHCCC reduces neuropathic or inflammatory hyperalgesia and not acute pain perception. Chronic
pain is known to be associated with plasticity ( ; ; ). An up-regulation ofMogil and McCarson 2000 Woolf and Salter 2000 Pace et al. 2006
the expression of group III mGluRs in sensory neurons of the pain pathway in neuropathy or inflammation could explain their lack of
effect in healthy animals. However, whereas expression of group I and II mGlu receptors have been shown to be up-regulated in
neuropathic or inflammatory pain models ( ; ; ; ), little isMills et al. 2001 Hudson et al. 2002 Mills and Hulsebosch 2002 Dolan et al. 2003
known about group III mGluRs. Thus, further experiments are needed to validate this hypothesis.
What could be the basis of group III mGluRs-induced attenuation of hyperalgesia? Group III mGluRs are presynaptic receptors,
located close to or in the active zone of the synapse, where they induce inhibition of synaptic transmission and neurotransmitter release
(except the purely retinal mGlu6) ( ). The inhibition of neurotransmitters release is mediated both by a directCartmell and Schoepp 2000
inhibition of exocytosis ( ) and by an inhibition of voltage-gated Ca  channels ( ; ;Chavis et al. 1998 2+ Takahashi et al. 1996 Perroy et al. 2000
; ). Almost all mGluRs are expressed in the spinal cord ( ; ; Capogna 2004 Guo and Ikeda 2005 Ohishi et al. 1995a Ohishi et al. 1995b Li et
; ; ), excepting two of the four group III mGluRs: mGlu6 which is located exclusively in the retinaal. 1997 Jia et al. 1999 Azkue et al. 2001
and mGlu8 ( ; ). Both mGlu4 and mGlu7 are present in presynaptic terminals from afferent fibers inValerio et al. 1997 Berthele et al. 1999
the dorsal horn of the spinal cord ( ; ; ; ) while mGlu8 is expressed inOhishi et al. 1995a Ohishi et al. 1995b Li et al. 1997 Azkue et al. 2001
most DRG cell bodies ( ). Accordingly, electrophysiological studies have shown that group III mGluRs activationCarlton and Hargett 2007
following L-AP4 infusion in dorsal horn reduces ascending informations in spinothalamic tracts resulting from mechanical noxious stimuli
( ). Moreover, in spinal cord slices, L-AP4 application decreases postsynaptic excitatory potentials occuring fromNeugebauer et al. 2000
afferent A fibers ( ). Since PHCCC produces antihyperalgesic effects similar to that of ACPT-I, the role of mGlu4 in thisGerber et al. 2000
phenomenon is particularly emphasized. However, the involvement of mGlu7 and mGlu8 can not be ruled out and their roles remain to be
elucidated.
Whatever the respective role of these receptors, the regulation of the release of glutamate they induce is certainly the main explanation
for their antihyperalgesic effect. Various studies are pointing out that hyperalgesia is paralleled by an increase in the release of excitatory
amino acids in the spinal cord. A transient increase of spinal glutamate and aspartate release has been observed following formalin or
carrageenin injection ( ; ) and in intramuscular pain model ( ).Sluka and Westlund 1993 Malmberg and Yaksh 1995 Skyba et al. 2005
Another illustration of the importance of spinal glutamate level in nociceptive transmission is underlined by the fact that inhibiting spinal
glutamate uptake by transporter inhibitors leads to spontaneous nociceptive behaviors and sensory hypersensitivity ( ).Liaw et al. 2005
Moreover, peripheral neuropathy induced by spinal nerve ligation comes with alterations of spinal glutamatergic neurotransmission which
contribute to allodynia and hyperalgesia. Indeed, an attenuation of glutamate transporters function is observed following spinal nerve
injury and may contribute to the pathophysiology of neuropathic pain ( ; ). Thus, the importance ofBinns et al. 2005 Liaw et al. 2005
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glutamatergic neurotransmission at the spinal cord level in the pathophysiology of maintained pain and the inhibitory role of group III
mGluRs on glutamate release strongly suggest that group III mGluRs agonists or modulators act as antihyperalgesic compounds by
reducing the high spinal glutamate levels associated with neuropathic or inflammatory pain.
In conclusion, the present study provides new evidences involving spinal group III mGluRs in the inhibition of hyperalgesia associated
with neuropathy or inflammation. Most particularly, it highlights the specific role of mGlu4 in hyperalgesia modulation. Based on their
key localization in the dorsal horn of spinal cord, on their functional roles and attenuation of behaviors observed in persistent animal pain
models that have been revealed to date, group III mGluRs in general and mGlu4 in particular can be considered as promising targets for
the design of novel treatments for chronic pain.
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Figure 1
ACPT-I is a selective group-III mGluRs agonist
A. Dose-response curves of ACPT-I on the different group III mGluRs. B. Lack of agonist activity of ACPT-I (100 M) on group I and groupμ
II mGluRs. While ACPT-I dose-dependently activates group-III mGluRs, even at high concentration ACPT-I fails to induce activity of
group-I and -II mGluRs. Receptor activity is determined by the accumulation of IP following the stimulation by various concentrations of
ACPT-I for group-III mGluRs and at a fixed concentration of 100 M for group-I and -II mGluRs. The results are expressed as the percentageμ
of the maximal activity induced by ACPT-I, each point corresponding to the mean  S.E.M. of triplicate. Data presented are representative of±
n 3 at least experiments. C. Interaction of ACPT-I with L-Glutamate uptake through x - transport system into rat brain membranes. Inhibition= c
of chloride dependent L- H-Glutamate (100 nM) uptake by ACPT-I or L-AP4 was measured into rat brain membranes in 50mM Tris-citrate3
buffer (pH7.4) in presence of 2.5 mM CaCl . Values are  of control (mean  S.E.M. of 3 independent experiments) and are corrected for2 % ±
non-specific uptake.
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Figure 2
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Effect of intrathecal administration of ACPT-I on pain evoked by mechanical, thermal or chemical stimuli in healthy animals
A. Effect of ACPT-I (20, 40, 80 g/rat, i.t.) on time-course of vocalization threshold to paw pressure. Morphine (10 g/rat, i.t.) is used as aμ μ
positive control. Results are expressed by the time-course curves of means  S.E.M. of vocalization threshold in grams (n 7 8 rats per group).± = –
B. Effect of ACPT-I on tail immersion time in hot water (46 C). Morphine (10 g/rat, i.t.) is used as a positive control. Results are expressed° μ
by the time-course of means  S.E.M. of the latency of tail withdrawal in seconds (n 7 8 rats per group). C. Effect of ACPT-I (2, 10, 20, 40,± = –
80 g/rat, i.t.) on nociceptive scores following formalin injection in rat hind paw. Morphine (10 g/rat, i.t.) is used as a positive control. Theμ μ
results are expressed as mean  S.E.M. of the cumulative biting and licking time during each phase (n 6 per group).± =
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Figure 3
Effect of intrathecal administration of ACPT-I on the vocalization threshold to paw pressure in inflammatory pain models: carrageenin-treated
rats (A) and monoarthritic rats (B)
Results are expressed by the time-course curves of mean  S.E.M. of vocalisation thresholds (g) in the left panel and by the area under curve±
in the right panel. Rats were treated with either vehicle, ACPT-I (2, 10, 20, 40, 80 g/rat, i.t.) or morphine (10 g/rat)(n  7 8 per group)μ μ = –
administrated 240 min after intraplantar injection of carrageenin or two weeks after intra-articular injection of complete Freund s adjuvant into’
the tibio-tarsal joint.  P < 0.05 vs. vehicle-treated group.*
Figure 4
Effect of intrathecal administration of ACPT-I on the vocalization threshold to paw pressure in neuropathic pain models: mononeuropathic
rats (A) and vincristine-treated rats (B)
Results are expressed by the time-course curves of means  S.E.M. of vocalization threshold (expressed in grams) in the left panel and by the±
area under curve (AUC, g. min) in the right panel. Two weeks after sciatic nerve ligature or following the first administration of vincristine,
rats were treated either with saline or ACPT-I (from 2 to 80 g/rat, i.t.)(n  7 8 rats per group).  P < 0.05 vs. vehicle-treated group.μ = – *
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Figure 5
Block of ACPT-I effect by group III-selective and non-selective mGluRs antagonists in inflammatory or neuropathic pain models
Time-course of the effect of the non-selective mGluRs antagonist LY341495 versus ACPT-I in carrageenin-treated rats B. Time-course of the
effect of the selective group-III mGluRs antagonist MAP4 versus ACPT-I in carrageenin-treated rats. C. Time-course of the effect of the
selective group-III mGluRs antagonist MAP4 versus ACPT-I in mononeuropathic rats. Results represented correspond to the time-course
curves of mean  S.E.M. of vocalisation thresholds (g) in the left panel and the corresponding area under curve (AUC, g. min) in the right±
panel. Rats were treated either with vehicle plus vehicle, ACPT-I (80 g/rat, i.t.) plus vehicle, ACPT-I (80 g/rat) plus MAP4 (from 25 to 100 μ μ
g/rat, as stated) or ACPT-I (80 g/rat) plus LY341495 (from 62.5 to 250 g/rat, as stated) (n  7 8 per group) administrated 240 min afterμ μ μ = –
intraplantar injection of carrageenin or two weeks after ligature of sciatic nerve.  P < 0.05 vs. vehicle-treated group.*
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Figure 6
Effect of intrathecal administration of mGlu4 positive allosteric modulator PHCCC on the vocalization threshold to paw pressure in healthy
rats (A), inflammatory (carrageenin-treated rats, B) or neuropathic pain models (mononeuropathic rats, C)
Results are expressed by the time-course curves of means  S.E.M. of vocalization threshold (expressed in grams) in the left panel and by the±
area under curve (AUC, g. min) in the right panel. Rats were treated either with vehicle, PHCCC (various doses as indicated in g/rat, i.t.) orμ
morphine (10 g/rat, i.t.) administrated 240 min after intraplantar injection of carrageenin or two weeks after ligature of sciatic nerve (n  7 8μ = –
per group).  P < 0.05 vs. vehicle-treated group.*
